Management of prostate cancer. Part 2: Localized and locally advanced disease

Expert Review of Anticancer Therapy

Volumn 6, Issue 4, 2006, Pages 595-603

  Sooriakumaran, Prasanna ^a   Kharsar, Sara Jane ^a   Shah, Jyoti ^b  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Localized; Locally advanced; Prostate cancer; Review; Treatment

Indexed keywords

ANTIANDROGEN; DOCETAXEL; GONADORELIN DERIVATIVE; HORMONE;

ADVANCED CANCER; AWARENESS; BRACHYTHERAPY; BREAST DISEASE; BREAST TENDERNESS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CRYOTHERAPY; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HUMAN; INTERSTITIAL RADIATION; LIBIDO DISORDER; MICROWAVE THERAPY; NIPPLE; PHOTODYNAMIC THERAPY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZATION; REVIEW; SALVAGE THERAPY; ULTRASOUND THERAPY; MALE; MORTALITY; PROSTATE TUMOR; SURVIVAL RATE;

HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 33746280855     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.4.595     Document Type: Review

References (70)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J. Clin. 54, 8-29 (2004).
2. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J. Natl Cancer Inst. 94, 958-960 (2002).
3. Vollmer RT, Humphrey PA. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. Am. J. Clin. Pathol. 116, 864-870 (2001).
4. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 281, 1395-1400 (1999).
5. Sooriakumaran P, Lovell DP, Henderson A et al. Gleason scoring varies among pathologists and this affects clinical risk in prostate cancer patients. Clin. Oncol. 17, 655-658 (2005).
6. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 5, 101-106 (2004).
7. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277, 1445-1451 (1997).
8. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Lancet Oncol. 24, 46-50 (2006).
9. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352, 1977-1984 (2005).
10. Bikbov BT, Tomilina NA. Some notes about the usage of the Charlson comorbidity index. Nephrol. Dial. Transplant. 19, 2926-2927 (2004).
11. Vicini FA, Martinez A, Hanks G et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 95, 2126-2135 (2002).
12. Potters L, Kattan MW, Reddy CA et al. Monotherapy for stage T1/T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 54, 9(11) (2002).
13. Kupelian PA, Potters L, Ciezki JP, Reddy CA, Reuther AM, Klein EA. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >72 Gy, permanent seed implantation, or combined seeds/ external beam radiotherapy for stage T1-T2 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 25-33 (2004).
14. Henderson A. Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? Eur. Urol. 45, 134-141 (2004).
15. Litwin MS. Accuracy of recall in health related quality of life assessment among men treated for prostate cancer. J. Clin. Oncol. 17, 2882-2888 (1999).
16. Langley SE, Laing R. Prostate brachytherapy has come of age: a review of the technique and results. BJU Int. 89, 241-249 (2002).
17. Penson DF, Feng Z, Kuniyuki A et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J. Clin. Oncol. 21, 1147-1154 (2003).
18. Theodorescu D. Cancer cryotherapy: evolution and biology. Rev. Urol. 6, S9-S19 (2004).
19. Derrick F, Britton JJ, Carter WC et al. Cryoablation of the prostate for localised prostate cancer: 8 year experience with 215 cases. J. Urol. 169, 459 (2003).
20. Bahn D, Lee F, Badalament R et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60, 3-11 (2002).
21. Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU Int. 93, 710-714 (2004).
22. Colombel M, Poissonnoer L, Gelet A. High intensity focused ultrasound for localised prostate cancer. Eur. Urol. 44, 21-24 (2004).
23. Thuroff S, Chaussy C, Vallancien G et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J. Endourol. 17, 673-677 (2003).
24. Gelet A, Chapelon J, Poissonnier L et al. Prostate cancer control with transrectal HIFU in 230 patients: five-year results. Eur. Urol. (Suppl. 3), 214 (2005).
25. Chaussy C, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr. Urol. Rep. 4, 248-252 (2003).
26. Chakrabarti P, Orihuela E, Egger N et al. Delta-aminolevulinic acid-mediated photosensitization of prostate cell lines: implication for photodynamic therapy of prostate cancer. Prostate 36, 211-218 (1998).
27. Sherar MD, Gertner MR, Yue CK et al. Interstitial microwave thermal therapy for prostate cancer: method of treatment and results of a Phase I/II trial. J. Urol. 166, 1707-1714 (2001).
28. Ahmed S. Emerging minimally invasive techniques for treating localized prostate cancer. BJU Int. 96, 1230-1234 (2005).
29. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 43, 316-381 (2004).
30. Chang CM, Moon D, Gianduzzo TR, Eden CG. The impact of prostate size in laparoscopic radical prostatectomy. Eur. Urol. 48, 285-290 (2005).
31. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292, 821-827 (2004).
32. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294, 1233-1239 (2005).
33. Meraney AM, Haese A, Palisaar J et al. Surgical management of prostate cancer: advances based on a rational approach to the data. Eur. J. Cancer 41, 888-907 (2005).
34. Boccon-Gibod L, Bertaccini A, Bono AV et al. Management of locally advanced prostate cancer: a European consensus. Int. J. Clin. Pract. 57, 187-194 (2003).
35. Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist 8, 259-269 (2003).
36. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 41, 113-120 (1993).
37. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur. Urol. 32, 385-390 (1997).
38. Roach M III, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol. 21, 1904-1911 (2003).
39. Vicini FA, Vargas C, Edmundson G, Kestin L, Martinez A. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin. Radiat. Oncol. 13, 98-108 (2003).
40. Klotz LH, Goldenberg SL, Jewett MA et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J. Urol. 170, 791-794 (2003).
41. Gomella LG, Zeltser I, Valicenti RK. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 62(Suppl. 1), 46-54 (2003).
42. Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J. Urol. 155, 1357-1360 (1996).
43. Goldenberg SL, Klotz LH, Srigley J et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J. Urol. 156, 873-877 (1996).
44. Aus G, Abrahamsson PA, Ahlgren G et al. Hormonal treatment before radical prostatectomy: a 3-year followup. J. Urol. 159, 2013-2017 (1998).
45. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 38, 706-713 (2000).
46. Pettaway CA, Pisters LL, Troncoso P et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J. Clin. Oncol. 18, 1050-1057 (2000).
47. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57, 281-285 (2001).
48. Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63, 1138-1142 (2004).
49. Pilepich MV, Krall JM, al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45, 616-623 (1995).
50. Laverdiere J, Nabid A, De Bedoya LD et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J. Urol. 171, 1137-1140 (2004).
51. Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 6, 841-850 (2005).
52. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285-1290 (2005).
53. Hanks G, Lu J, Machtay M et al. RTOG protocol 92-02: a Phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc. Am. Soc. Clin. Oncol. 19, 327a (2000).
54. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 97, 247-254 (2006).
55. Davis BJ, Pisansky TM, Leibovich BC. Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Curr. Opin. Urol. 13, 117-122 (2003).
56. Bolla M, Van Poppel, H, Van Cangh P et al. Does postoperative radiotherapy after RP improve progression-free survival in pT3N0 prostate cancer. Proc. Am. Soc. Clin. Oncol. 23, 382 (2004).
57. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572-578 (2005).
58. Hussain A, Dawson, N, Amin P et al. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/ locally advanced prostate cancer: preliminiary results. Semin. Oncol. 28, 22-31 (2001).
59. Fowler JE Jr, Bigler SA, White PC, Duncan WL. Hormone therapy for locally advanced prostate cancer. J. Urol. 168, 546-549 (2002).
60. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol. 164, 1579-1582 (2000).
61. Horwich A, Huddart RA, Gadd J et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br. J. Urol. 81, 96-99 (1998).
62. Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 53, 530-534 (1999).
63. Lane T, Ansell W, Williams G et al. Long-term outcomes in patients managed with intermittent androgen suppression. BJU Int. (Suppl. 1) (2002) (Abstract A82).
64. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291, 1325-1332 (2004).
65. Jani AB. Early prostate cancer: clinical decision-making. Lancet 361, 1045-1053 (2002).
66. Litwin MS, Hays RD, Fink A et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273, 129-135 (1995).
67. Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. J. Urol. 163, 851-857 (2000).
68. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J. Urol. 166, 947-952 (2001).
69. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 51, 614-623 (2001).
70. Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. N. Engl. J. Med. 347, 790-796 (2002).